Aggregation Tests Identify New Gene Associations with Breast Cancer in Populations with Diverse Ancestry

Background: Low-frequency variants play an important role in breast cancer (BC) susceptibility. Gene-based methods can increase power by combining multiple variants in the same gene and help identify target genes.

Methods: We evaluated the potential of gene-based aggregation in the Breast Cancer Association Consortium cohorts including 83,471 cases and 59,199 controls. Low-frequency variants were aggregated for individual genes' coding and regulatory regions. Association results in European ancestry samples were compared to single-marker association results in the same cohort. Gene-based associations were also combined in meta-analysis across individuals with European, Asian, African, and Latin American and Hispanic ancestry.

Results: In European ancestry samples, 14 genes were significantly associated (q < 0.05) with BC. Of those, two genes, FMNL3 (P = 6.11 × 10) and AC058822.1 (P = 1.47 × 10), represent new associations. High FMNL3 expression has previously been linked to poor prognosis in several other cancers. Meta-analysis of samples with diverse ancestry discovered further associations including established candidate genes ESR1 and CBLB. Furthermore, literature review and database query found further support for a biologically plausible link with cancer for genes CBLB, FMNL3, FGFR2, LSP1, MAP3K1, and SRGAP2C.

Conclusions: Using extended gene-based aggregation tests including coding and regulatory variation, we report identification of plausible target genes for previously identified single-marker associations with BC as well as the discovery of novel genes implicated in BC development. Including multi ancestral cohorts in this study enabled the identification of otherwise missed disease associations as ESR1 (P = 1.31 × 10), demonstrating the importance of diversifying study cohorts.

Citing Articles

Joint Screening for Ultra-High Dimensional Multi-Omics Data.

Tsafack U, Lin C, Ahn K Bioengineering (Basel). 2025; 11(12.

PMID: 39768011 PMC: 11727280. DOI: 10.3390/bioengineering11121193.

Lower mRNA Expression and Higher Levels of in HER2-Positive Breast Cancer.

Dix-Peek T, Dickens C, Valcarcel J, Duarte R Biology (Basel). 2024; 13(11).

PMID: 39596875 PMC: 11591975. DOI: 10.3390/biology13110920.

A proteome-wide association study identifies putative causal proteins for breast cancer risk.

Zhao T, Xu S, Ping J, Jia G, Dou Y, Henry J Br J Cancer. 2024; 131(11):1796-1804.

PMID: 39468330 PMC: 11589835. DOI: 10.1038/s41416-024-02879-1.

Integrating Single-Cell RNA-Seq and Bulk RNA-Seq to Construct a Novel γδT Cell-Related Prognostic Signature for Human Papillomavirus-Infected Cervical Cancer.

Wang X, Jin Y, Xu L, Tao S, Wu Y, Ao C Cancer Control. 2024; 31:10732748241274228.

PMID: 39206965 PMC: 11363054. DOI: 10.1177/10732748241274228.

Potential Role of Glyphosate, Glyphosate-Based Herbicides, and AMPA in Breast Cancer Development: A Review of Human and Human Cell-Based Studies.

Schluter H, Bariami H, Park H Int J Environ Res Public Health. 2024; 21(8).

PMID: 39200696 PMC: 11354939. DOI: 10.3390/ijerph21081087.

References

Stephens P, Tarpey P, Davies H, Van Loo P, Greenman C, Wedge D . The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-4. PMC: 3428862. DOI: 10.1038/nature11017. View

Amos C, Dennis J, Wang Z, Byun J, Schumacher F, Gayther S . The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol Biomarkers Prev. 2016; 26(1):126-135. PMC: 5224974. DOI: 10.1158/1055-9965.EPI-16-0106. View

Zeng Y, Xiao Y, Lu M, Luo X, Hu G, Deng K . Increased expression of formin-like 3 contributes to metastasis and poor prognosis in colorectal carcinoma. Exp Mol Pathol. 2015; 98(2):260-7. DOI: 10.1016/j.yexmp.2015.03.008. View

Liu X, Teng Y, Wu X, Li Z, Bao B, Liu Y . The E3 Ubiquitin Ligase Cbl-b Predicts Favorable Prognosis in Breast Cancer. Front Oncol. 2020; 10:695. PMC: 7219434. DOI: 10.3389/fonc.2020.00695. View

Easton D, Pooley K, Dunning A, Pharoah P, Thompson D, Ballinger D . Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447(7148):1087-93. PMC: 2714974. DOI: 10.1038/nature05887. View

Skol A, Sasaki M, Onel K . The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance. Breast Cancer Res. 2016; 18(1):99. PMC: 5048663. DOI: 10.1186/s13058-016-0759-4. View

Wojcik G, Graff M, Nishimura K, Tao R, Haessler J, Gignoux C . Genetic analyses of diverse populations improves discovery for complex traits. Nature. 2019; 570(7762):514-518. PMC: 6785182. DOI: 10.1038/s41586-019-1310-4. View

Gardberg M, Heuser V, Koskivuo I, Koivisto M, Carpen O . FMNL2/FMNL3 formins are linked with oncogenic pathways and predict melanoma outcome. J Pathol Clin Res. 2016; 2(1):41-52. PMC: 4858127. DOI: 10.1002/cjp2.34. View

Jiang D, McPeek M . Robust rare variant association testing for quantitative traits in samples with related individuals. Genet Epidemiol. 2013; 38(1):10-20. PMC: 4510991. DOI: 10.1002/gepi.21775. View

10.

Michailidou K, Lindstrom S, Dennis J, Beesley J, Hui S, Kar S . Association analysis identifies 65 new breast cancer risk loci. Nature. 2017; 551(7678):92-94. PMC: 5798588. DOI: 10.1038/nature24284. View

11.

Lei J, Shao J, Zhang J, Iglesia M, Chan D, Cao J . Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep. 2018; 24(6):1434-1444.e7. PMC: 6171747. DOI: 10.1016/j.celrep.2018.07.009. View

12.

Nasser J, Bergman D, Fulco C, Guckelberger P, Doughty B, Patwardhan T . Genome-wide enhancer maps link risk variants to disease genes. Nature. 2021; 593(7858):238-243. PMC: 9153265. DOI: 10.1038/s41586-021-03446-x. View

13.

Peterson R, Kuchenbaecker K, Walters R, Chen C, Popejoy A, Periyasamy S . Genome-wide Association Studies in Ancestrally Diverse Populations: Opportunities, Methods, Pitfalls, and Recommendations. Cell. 2019; 179(3):589-603. PMC: 6939869. DOI: 10.1016/j.cell.2019.08.051. View

14.

Jiang X, Finucane H, Schumacher F, Schmit S, Tyrer J, Han Y . Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019; 10(1):431. PMC: 6347624. DOI: 10.1038/s41467-018-08054-4. View

15.

Fejerman L, Ahmadiyeh N, Hu D, Huntsman S, Beckman K, Caswell J . Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25. Nat Commun. 2014; 5:5260. PMC: 4204111. DOI: 10.1038/ncomms6260. View

16.

Liu J, Chen S, Chen Y, Geng N, Feng C . High expression of FMNL3 associates with cancer cell migration, invasion, and unfavorable prognosis in tongue squamous cell carcinoma. J Oral Pathol Med. 2019; 48(6):459-467. DOI: 10.1111/jop.12857. View

17.

Ionita-Laza I, McCallum K, Xu B, Buxbaum J . A spectral approach integrating functional genomic annotations for coding and noncoding variants. Nat Genet. 2016; 48(2):214-20. PMC: 4731313. DOI: 10.1038/ng.3477. View

18.

Rappaport N, Twik M, Plaschkes I, Nudel R, Iny Stein T, Levitt J . MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search. Nucleic Acids Res. 2016; 45(D1):D877-D887. PMC: 5210521. DOI: 10.1093/nar/gkw1012. View

19.

Wang B, Matsuoka S, Ballif B, Zhang D, Smogorzewska A, Gygi S . Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science. 2007; 316(5828):1194-8. PMC: 3573690. DOI: 10.1126/science.1139476. View

20.

Milne R, Kuchenbaecker K, Michailidou K, Beesley J, Kar S, Lindstrom S . Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017; 49(12):1767-1778. PMC: 5808456. DOI: 10.1038/ng.3785. View